News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

iTeos Therapeutics To Present At The 2017 Wedbush PacGrow Healthcare Conference



8/8/2017 8:21:42 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Gosselies, Belgium - August 8, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that Michel Detheux, iTeos' Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 12:45 a.m. ET in New York, NY.

About iTeos Therapeutics SA
iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic ("cold") tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos' competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information, please visit www.iteostherapeutics.com.

For further information, please contact:

Michel Detheux, CEO
iTeos therapeutics
+32 71 919 933
michel.detheux@iteostherapeutics.com

Sarah McCabe
Stern Investor Relations, Inc.
+ 1 212 362-1200
sarah@sternir.com

Amber Fennell, Mathew Neal, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES